Nakamoto (NAKA)
Market Price (3/30/2026): $0.2268 | Market Cap: $46.1 MilSector: Financials | Industry: Diversified Capital Markets
Nakamoto (NAKA)
Market Price (3/30/2026): $0.2268Market Cap: $46.1 MilSector: FinancialsIndustry: Diversified Capital Markets
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Megatrend and thematic driversMegatrends include Health & Wellness Trends, and Aging Population & Chronic Disease. Themes include Medical Cannabis Therapeutics & Clinics, Geriatric Care, Show more. | Weak multi-year price returns2Y Excs Rtn is -121%, 3Y Excs Rtn is -161% | Penny stockMkt Price is 0.2 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -15 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -750% | ||
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 384% | ||
| Expensive valuation multiplesP/SPrice/Sales ratio is 24x | ||
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -31%, Rev Chg QQuarterly Revenue Change % is -40% | ||
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 110% | ||
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -851%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -35284% | ||
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 624% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -198% | ||
| High stock price volatilityVol 12M is 194% | ||
| Key risksNAKA key risks include [1] a potential Nasdaq delisting due to its low stock price, Show more. |
| Megatrend and thematic driversMegatrends include Health & Wellness Trends, and Aging Population & Chronic Disease. Themes include Medical Cannabis Therapeutics & Clinics, Geriatric Care, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -121%, 3Y Excs Rtn is -161% |
| Penny stockMkt Price is 0.2 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -15 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -750% |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 384% |
| Expensive valuation multiplesP/SPrice/Sales ratio is 24x |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -31%, Rev Chg QQuarterly Revenue Change % is -40% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 110% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -851%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -35284% |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 624% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -198% |
| High stock price volatilityVol 12M is 194% |
| Key risksNAKA key risks include [1] a potential Nasdaq delisting due to its low stock price, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Nakamoto (NAKA) stock has lost about 55% since 11/30/2025 because of the following key factors:
1. Significant Share Dilution from Strategic Acquisitions.
Nakamoto Inc. completed the acquisition of BTC Inc. and UTXO Management on February 20, 2026. This transaction was entirely financed through the issuance of 364,795,104 shares of Nakamoto common stock, valued at $81,632,852 based on the closing price on February 19, 2026. The substantial increase in outstanding shares likely led to significant dilution for existing shareholders, contributing to the stock's decline.
2. Persistent Negative Earnings and Weak Revenue Performance.
Prior to the acquisitions, Nakamoto (formerly KindlyMD, Inc.) demonstrated a history of poor financial performance. For the trailing 12 months ending September 30, 2025, the company reported earnings of -$90.5 million. The Q3 2025 earnings, reported on September 30, 2025, were -$86.0 million, with a reported revenue of only $388.21 thousand for the quarter ending September 30, 2025. Nakamoto had a 0% beat rate on analyst earnings estimates.
Show more
1. Significant Share Dilution from Strategic Acquisitions.
Nakamoto Inc. completed the acquisition of BTC Inc. and UTXO Management on February 20, 2026. This transaction was entirely financed through the issuance of 364,795,104 shares of Nakamoto common stock, valued at $81,632,852 based on the closing price on February 19, 2026. The substantial increase in outstanding shares likely led to significant dilution for existing shareholders, contributing to the stock's decline.
2. Persistent Negative Earnings and Weak Revenue Performance.
Prior to the acquisitions, Nakamoto (formerly KindlyMD, Inc.) demonstrated a history of poor financial performance. For the trailing 12 months ending September 30, 2025, the company reported earnings of -$90.5 million. The Q3 2025 earnings, reported on September 30, 2025, were -$86.0 million, with a reported revenue of only $388.21 thousand for the quarter ending September 30, 2025. Nakamoto had a 0% beat rate on analyst earnings estimates.
Show more
Stock Movement Drivers
Fundamental Drivers
The -54.8% change in NAKA stock from 11/30/2025 to 3/29/2026 was primarily driven by a -54.8% change in the company's P/S Multiple.| (LTM values as of) | 11302025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.50 | 0.23 | -54.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2 | 2 | 0.0% |
| P/S Multiple | 51.3 | 23.2 | -54.8% |
| Shares Outstanding (Mil) | 203 | 203 | 0.0% |
| Cumulative Contribution | -54.8% |
Market Drivers
11/30/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| NAKA | -54.8% | |
| Market (SPY) | -5.3% | 38.7% |
| Sector (XLF) | -10.0% | 33.0% |
Fundamental Drivers
The -95.8% change in NAKA stock from 8/31/2025 to 3/29/2026 was primarily driven by a -96.6% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 8312025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.44 | 0.23 | -95.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2 | 2 | -11.6% |
| P/S Multiple | 16.6 | 23.2 | 40.1% |
| Shares Outstanding (Mil) | 7 | 203 | -96.6% |
| Cumulative Contribution | -95.8% |
Market Drivers
8/31/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| NAKA | -95.8% | |
| Market (SPY) | 0.6% | 16.1% |
| Sector (XLF) | -10.8% | 13.8% |
Fundamental Drivers
nullnull
Market Drivers
2/28/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| NAKA | ||
| Market (SPY) | 9.8% | 17.0% |
| Sector (XLF) | -7.1% | 17.1% |
Fundamental Drivers
nullnull
Market Drivers
2/28/2023 to 3/29/2026| Return | Correlation | |
|---|---|---|
| NAKA | ||
| Market (SPY) | 69.4% | 17.0% |
| Sector (XLF) | 40.5% | 17.1% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| NAKA Return | - | - | - | - | -98% | -32% | -99% |
| Peers Return | 66% | -84% | 342% | 78% | 9% | -4% | 125% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -5% | 72% |
Monthly Win Rates [3] | |||||||
| NAKA Win Rate | - | - | - | - | 0% | 33% | |
| Peers Win Rate | 48% | 31% | 77% | 48% | 58% | 33% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| NAKA Max Drawdown | - | - | - | - | -98% | -35% | |
| Peers Max Drawdown | -9% | -84% | -5% | -43% | -44% | -20% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -5% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: MSTR, MARA, RIOT, COIN, HUT.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/27/2026 (YTD)
How Low Can It Go
NAKA has limited trading history. Below is the Financials sector ETF (XLF) in its place.
| Event | XLF | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -26.9% | -25.4% |
| % Gain to Breakeven | 36.7% | 34.1% |
| Time to Breakeven | 525 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -43.3% | -33.9% |
| % Gain to Breakeven | 76.5% | 51.3% |
| Time to Breakeven | 295 days | 148 days |
| 2018 Correction | ||
| % Loss | -26.1% | -19.8% |
| % Gain to Breakeven | 35.2% | 24.7% |
| Time to Breakeven | 338 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -83.7% | -56.8% |
| % Gain to Breakeven | 515.2% | 131.3% |
| Time to Breakeven | 4,470 days | 1,480 days |
Compare to MSTR, MARA, RIOT, COIN, HUT
In The Past
SPDR Select Sector Fund's stock fell -26.9% during the 2022 Inflation Shock from a high on 1/12/2022. A -26.9% loss requires a 36.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Nakamoto (NAKA)
Kindly MD, Inc. (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis. The Company offers evaluation and management, including, but not limited to chronic pain, functional medicine, cognitive behavioral therapy, trauma and addiction therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, medically managed weight loss, and hormone therapy. Through its focus on an embedded model of prescriber and therapist teams, KindlyMD develops patient-specific care programs with a specific mission to reduce opioid use in the patient population while successfully treating patients with effective and evidence-based non-opioid alternatives in close conjunction with behavioral therapy. Beyond its treatment of patients, KindlyMD collects data focused on why and how patients turn to alternative treatments to reduce prescription medication use and addiction. The Company captures all relevant datapoints to assist and appropriately treat each individual patient. This also results in valuable data for the Company and the Company’s investors. We strive to become a source for evidence-based guidelines, data, treatment models, and education in the fight against the opioid crisis in America. Business Revenue Streams We currently earn revenue through (i) patient care services related to medical evaluation and treatment and (ii) product retail sales. Our forecasted plan is to operate across various revenue streams: (i) medical evaluation and treatment visits reimbursed by Medicare, Medicaid, and commercial insurance payers as well as self-pay services, (ii) data collection and research, (iii) education partnerships, (iv) service affiliate agreements, and (v) retail sales. Our principal executive offices are located at 5097 S 900 E, Suite 100 Salt Lake City, UT.
AI Analysis | Feedback
1. Livongo Health for holistic pain management and opioid addiction.
2. 'One Medical' for chronic pain and opioid reduction, but with a mission to be a leading data platform for the opioid crisis.
AI Analysis | Feedback
- Holistic Pain Management and Addiction Treatment Services: Provides integrated medical and behavioral health services aimed at reducing opioid use and treating chronic pain, addiction, and related conditions.
- Healthcare Data Collection and Research: Gathers valuable data on patient responses to alternative treatments and addiction patterns to inform evidence-based guidelines.
- Retail Product Sales: Sells various products, contributing to a current and forecasted revenue stream.
- Healthcare Education Partnerships: Engages in collaborations to educate healthcare providers and the public on non-opioid treatments and addiction prevention.
- Service Affiliate Agreements: Establishes partnerships for broader service delivery and market penetration.
AI Analysis | Feedback
KindlyMD, operating under the symbol NAKA, primarily serves individual patients directly. Based on the company's description, its major customer categories are:
-
Chronic Pain Patients: Individuals seeking holistic, evidence-based, and non-opioid alternatives for managing chronic pain, with a focus on reducing opioid use and dependency.
-
Patients at Risk of or Recovering from Opioid Addiction/Dependency: Individuals who are seeking to prevent or reduce addiction and dependency on opiates, including those needing recovery support services, overdose education, and trauma/addiction therapy.
-
Individuals Seeking General Health and Wellness Services: Patients utilizing services such as functional medicine, cognitive behavioral therapy, preventative medicine, medically managed weight loss, hormone therapy, and limited urgent care services, which contribute to overall well-being beyond specific pain or addiction treatment.
AI Analysis | Feedback
nullAI Analysis | Feedback
nullAI Analysis | Feedback
The key risks for KindlyMD (NAKA) are:
- Reimbursement and Regulatory Risk: KindlyMD's current and forecasted revenue streams rely heavily on patient care services reimbursed by Medicare, Medicaid, and commercial insurance payers. Therefore, changes in government healthcare policies, insurance company reimbursement rates, or stricter regulations concerning pain management, opioid alternatives, and behavioral health services could significantly impact the company's financial viability and operational model.
- Data Privacy, Security, and Monetization Risk: As a "healthcare data company" that plans to generate revenue from data collection and research, KindlyMD faces substantial risks related to data privacy and security. Handling sensitive health information necessitates strict compliance with regulations like HIPAA. Data breaches, non-compliance with privacy laws, or difficulties in monetizing healthcare data due to regulatory hurdles or limited market demand could lead to significant financial penalties, reputational damage, and hinder a key forecasted revenue stream.
- Market Adoption and Efficacy of Treatment Model Risk: KindlyMD's core mission is to reduce opioid use through an integrated model of prescriber and therapist teams employing "effective and evidence-based non-opioid alternatives." The success of the business depends on the widespread acceptance and proven efficacy of this treatment model. If their methods do not gain broad market adoption among patients and healthcare providers, or if the long-term effectiveness is not adequately demonstrated or questioned, it could negatively impact patient acquisition, partnership opportunities, and the company's ability to establish itself as a credible source for treatment guidelines.
AI Analysis | Feedback
The potential emergence of large technology companies (e.g., Google, Apple, Amazon, Microsoft) leveraging their significant data infrastructure and advanced AI/machine learning capabilities to enter the specialized market of holistic pain management and opioid addiction treatment. These entities could develop highly scalable, data-driven digital platforms offering personalized treatment programs and evidence-based guidelines, potentially surpassing KindlyMD's ability to collect and leverage proprietary data and provide integrated care on a broader scale, thus directly challenging KindlyMD's core services and its ambition to become a leading source for data and treatment models.AI Analysis | Feedback
Nakamoto Inc. (NAKA), which operates its healthcare services through its wholly-owned subsidiary KindlyMD, Inc., addresses several significant markets within the healthcare sector in the United States.
The primary addressable markets for Nakamoto's main products and services are:
- Addiction Treatment Market (U.S.): The U.S. addiction treatment market was valued at an estimated USD 2.44 billion in 2024 and is projected to grow to approximately USD 4.31 billion by 2034, demonstrating a Compound Annual Growth Rate (CAGR) of 5.85% from 2025 to 2034. North America, predominantly the U.S., accounted for 37% of the global addiction treatment market in 2024.
- Opioid Use Disorder (OUD) Treatment Market (U.S.): The U.S. market for opioid use disorder treatment is substantial, with an estimated value of USD 3.37 billion in 2025, projected to reach about USD 9.48 billion by 2035, growing at a CAGR of 10.9% from 2026 to 2035. Another report estimates the U.S. OUD market at USD 3.92 billion in 2025, with a projected increase to USD 9.27 billion by 2034 at a CAGR of 9.70% from 2026–2034.
- Behavioral Health Services Market (U.S.): This market, encompassing services like cognitive behavioral therapy and trauma therapy, was valued at USD 66.79 billion in 2025 and is expected to exceed USD 96.80 billion by 2035, with a CAGR of 3.78% from 2026 to 2035. Other estimates place the U.S. behavioral health market at over USD 89 billion in 2024, anticipated to reach USD 165.4 billion by 2034 with a 6.4% CAGR from 2025 to 2034.
- Chronic Pain Management Market (U.S.): The U.S. pain management market, which includes various therapies beyond just pharmaceuticals, was valued at USD 31.18 billion in 2025, projected to reach USD 42.87 billion by 2034, growing at a CAGR of 3.6% from 2026 to 2034. The broader chronic pain market in the U.S. was valued at USD 21.2 billion in 2023 and is expected to reach USD 28.9 billion by 2034.
- Mental Health and Addiction Treatment Centers Market (U.S.): A more comprehensive market that combines mental health and addiction treatment services was estimated at USD 143.62 billion in 2024 and is projected to reach USD 408.12 billion by 2033, expanding at a CAGR of 12.3% from 2025 to 2033.
- Healthcare Data Analytics Market (U.S.): KindlyMD's focus on data collection and research falls within the U.S. healthcare analytics market, which was estimated at USD 21.21 billion in 2024 and is projected to reach USD 67.48 billion by 2033, with a CAGR of 12.76% from 2025 to 2033. The U.S. healthcare big data analytics market was valued at USD 24.7 billion in 2025 and is projected to reach USD 62.43 billion by 2034.
AI Analysis | Feedback
The following are 3-5 expected drivers of future revenue growth for Nakamoto (NAKA) over the next 2-3 years:- Expansion of Patient Care Services and Payer Coverage: KindlyMD anticipates significant revenue growth through the expansion of its medical evaluation and treatment visits. This includes increasing patient volume for existing services, broadening the range of specialized outpatient clinical services such as chronic pain management, functional medicine, and various therapies, and securing wider reimbursement from Medicare, Medicaid, and commercial insurance payers, in addition to self-pay services.
- Monetization of Data Collection and Research: A key driver will be the establishment of data collection and research as a dedicated revenue stream. KindlyMD collects valuable data on patient responses to alternative treatments and opioid reduction strategies, which it intends to leverage for commercial purposes.
- Development of Education Partnerships: The company plans to generate revenue through education partnerships. As KindlyMD aims to become a source for evidence-based guidelines, treatment models, and education in addressing the opioid crisis, these partnerships will provide a new avenue for growth.
- Formation of Service Affiliate Agreements: KindlyMD expects future revenue growth from establishing service affiliate agreements, indicating a strategy to partner with other entities to extend its service reach or offerings.
AI Analysis | Feedback
Share Repurchases
- In December 2025, KindlyMD authorized a share repurchase program for up to $10 million of its outstanding common stock.
- As of available records, no actual share repurchases have been made under the authorized program.
Share Issuance
- In August 2025, KindlyMD announced a $5 billion at-the-market (ATM) equity offering program to be used for general corporate purposes, including its Bitcoin Treasury Strategy, working capital, acquisitions, and capital expenditures.
- As part of its merger with Nakamoto Holdings Inc. in August 2025, KindlyMD engaged in a $710 million Private Investment in Public Equity (PIPE) offering, consisting of $510 million in common shares and pre-funded warrants, and $200 million in senior secured convertible notes.
- In February 2026, Nakamoto Inc. issued approximately 364.8 million shares of common stock, valued at about $81.6 million, to complete the all-stock acquisitions of BTC Inc. and UTXO Management.
Inbound Investments
- KindlyMD raised approximately $540 million from a private placement and secured $200 million in convertible notes in August 2025 as part of its merger with Nakamoto Holdings Inc., intended to fund Bitcoin purchases.
Outbound Investments
- In August 2025, KindlyMD acquired 5,743.91 Bitcoin for approximately $679 million, bringing its total holdings to 5,764.91 BTC.
- In February 2026, Nakamoto Inc. completed the acquisitions of BTC Inc. and UTXO Management through an all-stock transaction valued at roughly $81.6 million, expanding its Bitcoin-native enterprise portfolio.
Capital Expenditures
- Nakamoto Inc. reported capital expenditures of $13.3K in December 2021.
- In Q3 2024, capital expenditures by Nakamoto Inc. were $2.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Kindly MD Earnings Notes | 12/16/2025 | |
| Can Kindly MD Stock Recover If Markets Fall? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to NAKA.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | NDAQ | Nasdaq | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | JEF | Jefferies Financial | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | ALAB | Astera Labs | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | 0.0% | 0.0% | 0.0% |
| 02272026 | PAYO | Payoneer Global | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | 0.0% | 0.0% | 0.0% |
| 02272026 | FOUR | Shift4 Payments | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 0.0% | 0.0% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 30.10 |
| Mkt Cap | 4.8 |
| Rev LTM | 562 |
| Op Inc LTM | -179 |
| FCF LTM | -964 |
| FCF 3Y Avg | -604 |
| CFO LTM | -103 |
| CFO 3Y Avg | -56 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 6.2% |
| Rev Chg 3Y Avg | 39.3% |
| Rev Chg Q | -13.6% |
| QoQ Delta Rev Chg LTM | -3.9% |
| Op Mgn LTM | -71.8% |
| Op Mgn 3Y Avg | -70.4% |
| QoQ Delta Op Mgn LTM | -15.3% |
| CFO/Rev LTM | -88.5% |
| CFO/Rev 3Y Avg | -69.6% |
| FCF/Rev LTM | -2,453.7% |
| FCF/Rev 3Y Avg | -1,003.3% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 4.8 |
| P/S | 15.3 |
| P/EBIT | -4.5 |
| P/E | -4.5 |
| P/CFO | -5.7 |
| Total Yield | -12.6% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -20.1% |
| D/E | 0.2 |
| Net D/E | 0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -9.3% |
| 3M Rtn | -18.5% |
| 6M Rtn | -49.4% |
| 12M Rtn | -21.5% |
| 3Y Rtn | 95.6% |
| 1M Excs Rtn | -4.4% |
| 3M Excs Rtn | -11.8% |
| 6M Excs Rtn | -45.2% |
| 12M Excs Rtn | -40.9% |
| 3Y Excs Rtn | 21.7% |
Price Behavior
Price Behavior
| Market Price | $0.23 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 05/31/2024 | |
| Distance from 52W High | -99.1% | |
| 50 Days | 200 Days | |
| DMA Price | $11.43 | $11.43 |
| DMA Trend | down | down |
| Distance from DMA | -98.0% | -98.0% |
| 3M | 1YR | |
| Volatility | 104.5% | 194.2% |
| Downside Capture | 2.91 | 3.33 |
| Upside Capture | 329.58 | -211.04 |
| Correlation (SPY) | 38.7% |
NAKA Betas & Captures as of 2/28/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 4.56 | 3.92 | 3.98 | 2.75 | 1.05 | 1.14 |
| Up Beta | 9.15 | 4.25 | 4.55 | 0.55 | -0.84 | -0.79 |
| Down Beta | -0.60 | 1.21 | 1.68 | 2.99 | 0.20 | 2.46 |
| Up Capture | 190% | 355% | 264% | -130% | -44% | -5% |
| Bmk +ve Days | 9 | 20 | 31 | 70 | 142 | 431 |
| Stock +ve Days | 7 | 14 | 21 | 44 | 64 | 64 |
| Down Capture | 618% | 501% | 470% | 335% | 169% | 108% |
| Bmk -ve Days | 12 | 21 | 30 | 54 | 109 | 320 |
| Stock -ve Days | 14 | 27 | 40 | 80 | 126 | 126 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NAKA | |
|---|---|---|---|---|
| NAKA | -98.9% | 194.5% | -1.86 | - |
| Sector ETF (XLF) | -4.0% | 19.2% | -0.33 | 16.9% |
| Equity (SPY) | 14.5% | 18.9% | 0.59 | 16.7% |
| Gold (GLD) | 50.2% | 27.7% | 1.46 | -1.2% |
| Commodities (DBC) | 17.8% | 17.6% | 0.85 | 4.4% |
| Real Estate (VNQ) | 0.4% | 16.4% | -0.15 | 3.1% |
| Bitcoin (BTCUSD) | -23.7% | 44.2% | -0.49 | 22.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NAKA | |
|---|---|---|---|---|
| NAKA | -59.5% | 194.5% | -1.86 | - |
| Sector ETF (XLF) | 9.1% | 18.7% | 0.37 | 16.9% |
| Equity (SPY) | 11.8% | 17.0% | 0.54 | 16.7% |
| Gold (GLD) | 20.7% | 17.7% | 0.96 | -1.2% |
| Commodities (DBC) | 11.6% | 18.9% | 0.50 | 4.4% |
| Real Estate (VNQ) | 3.0% | 18.8% | 0.07 | 3.1% |
| Bitcoin (BTCUSD) | 4.0% | 56.6% | 0.29 | 22.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NAKA | |
|---|---|---|---|---|
| NAKA | -36.4% | 194.5% | -1.86 | - |
| Sector ETF (XLF) | 12.0% | 22.1% | 0.50 | 16.9% |
| Equity (SPY) | 14.0% | 17.9% | 0.67 | 16.7% |
| Gold (GLD) | 13.3% | 15.8% | 0.70 | -1.2% |
| Commodities (DBC) | 8.2% | 17.6% | 0.39 | 4.4% |
| Real Estate (VNQ) | 4.7% | 20.7% | 0.19 | 3.1% |
| Bitcoin (BTCUSD) | 66.4% | 66.8% | 1.06 | 22.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/19/2025 | -9.6% | -7.2% | -23.8% |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 1 | 1 | 1 |
| Median Positive | |||
| Median Negative | -9.6% | -7.2% | -23.8% |
| Max Positive | |||
| Max Negative | -9.6% | -7.2% | -23.8% |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.